Zambia Begins First Preventive Hiv Vaccine Trial


Exhibit 99.1
Investor and Media Contact:
Stacie D. Byars
Director, Communications
Targeted Genetics Corporation
(206) 521-7392

Lusaka, Zambia and Seattle, Washington, USA—April 26, 2006—The Zambia Emory HIV Research Project(ZEHRP), the International AIDS Vaccine Initiative (IAVI) and Targeted Genetics Corporation(Nasdaq: TGEN) today announced the initiation of a clinical trial in Zambia to test the safety andimmunogenicity of tgAAC09, a preventive HIV vaccine.
This is the first preventive HIV vaccine trial to be conducted in Zambia, and will take place atthe Zambia Emory HIV Research Project Center in Lusaka with Dr. Elwyn Chomba acting as thePrincipal Investigator. It is an early-stage, multi-national trial, also being conducted at threesites in South Africa and Uganda.
“Zambia is proud today to be among the leading countries in Africa to spearhead the testing ofvaccine candidates, given their great potential for the prevention of HIV/AIDS,” said Dr. ElwynChomba, ZEHRP and Principal Investigator for the trial.
“IAVI is pleased to be working with the excellent team at ZEHRP. Supported by the government ofZambia, and in collaboration with the scientific and medical community in Lusaka, the Zambia EmoryHIV Research Project has contributed to HIV/AIDS prevention in the country,” said Seth Berkley,President and CEO of IAVI. “The Zambia study, along with other vaccine trials worldwide, will helpus all take the field one step further in our search for a preventive HIV vaccine.”
The vaccine candidate, tgAAC09, was developed by Targeted Genetics, based in Seattle. The vaccineis based on HIV subtype C, the subtype of the virus most prevalent in southern Africa. tgAAC09 isdesigned as a preventive vaccine, intended to protect people not infected with HIV from contractingthe disease. It is designed to elicit two different types of immune responses — an antibodyresponse and a cell-mediated response.
“Expanding the evaluation of tgAAC09 to another region in need further advances the development ofthis vaccine candidate. We continue to be optimistic about the potential of AAV-based vaccines inthe fight against HIV/AIDS and are pleased to be working in partnership with IAVI and ZEHRP insupport of the global effort to halt the HIV pandemic. This is another example of the kind of



international collaboration that is critical to an expedited pursuit of an effective vaccine,” saidH. Stewart Parker, President and Chief Executive Officer of Targeted Genetics.
About the Vaccine Candidate
The vaccine candidate, tgAAC09, utilizes a recombinant adeno-associated viral vector (AAV) that wasdeveloped with and manufactured by Targeted Genetics. Under the terms of a public-privatecollaboration, IAVI is funding development, pre-clinical and clinical studies to test the vaccine.The early-stage trial follows positive safety data received from the Phase I trial conducted overthe past two years in Belgium, Germany, and India where volunteers received a lower-dose range.
Targeted Genetics’ AAV development process is based on a cell line which was designed by Philip R.Johnson, MD., at the Children’s Research Institute on the campus of Children’s Hospital, inColumbus, Ohio, USA. Dr. Johnson is now Chief Scientific Officer at the Children’s Hospital ofPhiladelphia, Pennsylvania, USA.
About the Trial
The trial should take about 18 months to complete. At the Lusaka clinical trial site, 16 volunteers(men and women) who are in good health will be enrolled. IAVI estimates that there are 30preventive HIV vaccine candidates in human trials on six continents.
About IAVI
The International AIDS Vaccine Initiative (IAVI) is a global not-for-profit organization working toaccelerate the development of a vaccine to prevent HIV infection and AIDS. Founded in 1996 andoperational in 23 countries, IAVI and its network of collaborators research and develop vaccinecandidates. IAVI also advocates for a vaccine to be a global priority and works to ensure that afuture vaccine will be accessible to all who need it. IAVI’s financial and in-kind supportersinclude the Bill & Melinda Gates Foundation, the New York Community Trust, the RockefellerFoundation, the Starr Foundation, the Governments of the Basque Country, Canada, Denmark, theEuropean Union, Ireland, the Netherlands, Norway, Sweden, the United Kingdom, and the UnitedStates; multilateral organizations such as the World Bank; corporate donors including BD (Becton,Dickinson & Co.), Continental Airlines, DHL and Pfizer; leading AIDS charities such as BroadwayCares/Equity Fights AIDS, Crusaid, Deutsche AIDS-Stiftung, and the Until There’s A Cure Foundation;other private donors such as the Haas Charitable Trusts; and many generous individuals from aroundthe world. For more information, see
The Zambia Emory HIV Research Project (ZEHRP), located in Lusaka, Zambia. The ZEHRP Ndola and Kitwesites located in the Copperbelt and their sister project, Project San Francisco (PSF), located inKigali, Rwanda, comprise the Rwanda Zambia HIV Research Group (RZHRG). The organization works withcouples and has ongoing studies to 1) promote couples voluntary counseling and testing (CVCT), 2)measure the transmission between discordant (one HIV-positive and one HIV-negative) couples(Heterosexual Transmission study) and 3) assess the contraceptive choices of women (Family Planningstudy). The RZHRG sites are also currently participating in a multi-site Phase III clinical trialassessing the effect of Acyclovir in lowering the transmission of HIV in discordant couples. TheLusaka site was established in 1994 when Project San Francisco relocated to Zambia during theRwandan genocide. ZEHRP boasts three CVCT centres as well as a well-equipped immunology andclinical laboratory.
About Targeted Genetics
Targeted Genetics Corporation (Nasdaq: TGEN) is a biotechnology company committed to thedevelopment and commercialization of innovative targeted molecular therapies for the prevention andtreatment of inflammatory arthritis, HIV/AIDS and other acquired and inherited diseases with



significant unmet medical need. Targeted Genetics uses its considerable knowledge and capabilitiesin the development and manufacturing of gene delivery technologies to advance a diverse productdevelopment pipeline. Its product development efforts target inflammatory arthritis, HIV/AIDS,congestive heart failure, Huntington’s disease and hyperlipidemia. To learn more about TargetedGenetics, visit its website at
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
This release contains forward-looking statements regarding the data to be collected in this trial,the establishment or determination of efficacy endpoints from the data collected in the trial, thetimely and complete accrual of patients in the trial and our ability to commercialize tgAAC94, ourexpected use of these proceeds and other statements about our plans, objectives, intentions andexpectations. These statements, involve current expectations, forecasts of future events and otherstatements that are not historical facts. Inaccurate assumptions and known and unknown risks anduncertainties can affect the accuracy of forward-looking statements. Factors that could affect ouractual results include, but are not limited to, our ability to obtain, maintain and protect ourintellectual property, our ability to raise capital when needed, our ability to recruit and enrollsuitable trial participants, the timing, nature and results of research and clinical trials,potential development of alternative technologies or more effective processes by competitors, and,our ability to obtain and maintain regulatory or institutional approvals,, as well as other riskfactors described in the section entitled “Factors Affecting Our Operating Results, Our Businessand Our Stock Price” in our report on Form 10-K for the year ended December 31, 2005. You shouldnot rely unduly on these forward-looking statements, which apply only as of the date of thisrelease. We undertake no duty to publicly announce or report revisions to these statements as newinformation becomes available that may change our expectations.
Katherine Moore, IAVI, New York, + 212 847 1097
Ellena Friedman, IAVI, New York, +212 847 1090/+646 755 1973
Stacie D. Byars, Targeted Genetics, Seattle, + 206 521 7392/ +206 660 2588

# # #